Nationwide Fund Advisors’s Seres Therapeutics MCRB Stock Holding History

Nationwide Fund Advisors’s Portfolio MCRB Stock Details MCRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-516	Closed	-$166K	–	1218
2017 Q3	$166K	Hold	516	–	–	﹤0.01%	2713
2017 Q2	$117K	Hold	516	–	–	﹤0.01%	2842
2017 Q1	$116K	Sell	516 -64	-11%	-$13K	﹤0.01%	2797
2016 Q4	$115K	Hold	580	–	–	﹤0.01%	2827
2016 Q3	$143K	Hold	580	–	–	﹤0.01%	2779
2016 Q2	$337K	Buy	580 +308	+113%	+$181K	﹤0.01%	2359
2016 Q1	$145K	Sell	272 -3	-1%	-$1.57K	﹤0.01%	2673
2015 Q4	$193K	Buy	275 +177	+181%	+$116K	﹤0.01%	2576
2015 Q3	$58K	Buy	+98	New	+$79.9K	﹤0.01%	3011

Other funds holding MCRB

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Nationwide Fund Advisors's MCRB Position: Q4 2017 in Review

Nationwide Fund Advisors sold out of Seres Therapeutics (MCRB) in Q4 2017, closing a stake of 516 shares — an estimated $166K sold.

Nationwide Fund Advisors first reported a position in MCRB in Q3 2015 and held it in 9 quarters. The position peaked at $337K in Q2 2016. 85 funds tracked by Wall St. Rank hold MCRB as of Q4 2017.

Nationwide Fund Advisors reported no remaining Seres Therapeutics position as of Q4 2017 after selling out during the quarter.
Nationwide Fund Advisors sold 516 Seres Therapeutics shares in Q4 2017, an estimated $166K.
Nationwide Fund Advisors first reported a position in Seres Therapeutics in Q3 2015 and held it in 9 quarters.
Nationwide Fund Advisors's Seres Therapeutics position peaked at $337K in Q2 2016.
85 funds tracked by Wall St. Rank held Seres Therapeutics as of Q4 2017.

Based on Nationwide Fund Advisors's 13F filing for Q4 2017, filed 1 Feb 2018.